Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.
Here's a review of the key highlights from the company's big announcement:
First, Novavax said that its phase 3 Prepare trial -- which is studying its respiratory syncytial virus candidate, RSV F Vaccine, in infants via maternal immunization -- continues to progress. The company said that it is actively enrolling patients at 80 sites in 11 countries.
Source: Fool.com
Novavax Inc. Stock
€15.03
-4.630%
Our community is currently high on Novavax Inc. with 4 Buy predictions and 1 Sell predictions.
With a target price of 22 € there is a positive potential of 46.33% for Novavax Inc. compared to the current price of 15.03 €.
